MNPR
Monopar Therapeutics
NASDAQ · Healthcare · Biotechnology · US
$96.47
−6.07%Next report
Analyst consensus
- Next report date
- Nov 12, 2026
- EPS estimate
- -$0.86
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 12, 2026
- EPS actual
- -$0.62
- EPS estimate
- -$0.64
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 8
- EPS misses (12Q)
- 4
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +9.2%
- Revenue beats (12Q)
- —
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $131
- PT range
- $119 – $145
- Analysts
- 4
3 Buy1 Hold0 Sell
No earnings call summaries available
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Aug 12, 2026 | -$0.64 | -$0.62 | Beat 3.51% | — |
| May 14, 2026 | -$1.06 | -$0.46 | Beat 56.60% | — |
| Mar 27, 2026 | -$0.51 | -$0.61 | Miss -19.08% | — |
| Nov 13, 2025 | -$0.46 | -$0.48 | Miss -4.35% | — |
| Aug 12, 2025 | -$0.47 | -$0.35 | Beat 25.53% | — |
| Mar 31, 2025 | -$0.36 | -$2.23 | Miss -519.44% | — |
| Nov 8, 2024 | -$0.46 | -$0.37 | Beat 19.57% | — |
| Aug 9, 2024 | -$0.45 | -$0.50 | Miss -11.11% | — |
| May 9, 2024 | -$0.85 | -$0.50 | Beat 41.18% | — |
| Nov 9, 2023 | -$0.95 | -$0.70 | Beat 26.32% | — |
| Aug 10, 2023 | -$0.95 | -$0.80 | Beat 15.79% | — |
| May 11, 2023 | -$1.00 | -$0.95 | Beat 5.00% | — |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 12, 2026